JP2016216465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016216465A5 JP2016216465A5 JP2016114725A JP2016114725A JP2016216465A5 JP 2016216465 A5 JP2016216465 A5 JP 2016216465A5 JP 2016114725 A JP2016114725 A JP 2016114725A JP 2016114725 A JP2016114725 A JP 2016114725A JP 2016216465 A5 JP2016216465 A5 JP 2016216465A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically active
- active compound
- composition according
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 17
- 229920000642 polymer Polymers 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000004005 microsphere Substances 0.000 claims 4
- 239000000178 monomer Substances 0.000 claims 3
- 229940124638 COX inhibitor Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000003073 embolic effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- -1 camptothecin compound Chemical class 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 125000003010 ionic group Chemical group 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003016 phosphoric acids Chemical class 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000010526 radical polymerization reaction Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
- 229950009819 zotarolimus Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0716003.9 | 2007-08-16 | ||
| GB0716003A GB0716003D0 (en) | 2007-08-16 | 2007-08-16 | Delivery of drug combinations |
| EP07121158.5 | 2007-11-20 | ||
| EP07121158 | 2007-11-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014016185A Division JP2014114307A (ja) | 2007-08-16 | 2014-01-30 | 薬剤の組み合わせの送達 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016216465A JP2016216465A (ja) | 2016-12-22 |
| JP2016216465A5 true JP2016216465A5 (https=) | 2017-04-27 |
Family
ID=39941549
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520637A Pending JP2010536738A (ja) | 2007-08-16 | 2008-08-18 | 薬剤の組み合わせの送達 |
| JP2014016185A Pending JP2014114307A (ja) | 2007-08-16 | 2014-01-30 | 薬剤の組み合わせの送達 |
| JP2016114725A Pending JP2016216465A (ja) | 2007-08-16 | 2016-06-08 | 薬剤の組み合わせの送達 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520637A Pending JP2010536738A (ja) | 2007-08-16 | 2008-08-18 | 薬剤の組み合わせの送達 |
| JP2014016185A Pending JP2014114307A (ja) | 2007-08-16 | 2014-01-30 | 薬剤の組み合わせの送達 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110229572A1 (https=) |
| EP (1) | EP2190409B9 (https=) |
| JP (3) | JP2010536738A (https=) |
| ES (1) | ES2706023T3 (https=) |
| TR (1) | TR201820076T4 (https=) |
| WO (1) | WO2009022190A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1985286A1 (en) * | 2007-04-24 | 2008-10-29 | Biocompatibles UK Limited | Microspheres for treatment of brain tumours |
| US20140378404A1 (en) * | 2011-10-25 | 2014-12-25 | Nektar Therapeutics | Treatment of Patients Suffering from Cancer |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| ES2913851T3 (es) * | 2018-02-23 | 2022-06-06 | Van Rijn Beheer B V | Microesferas de embolización porosas que comprenden fármacos |
| JP2022502531A (ja) | 2018-10-12 | 2022-01-11 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイションUniversity of Pittsburgh − Of the Commonwealth System of Higher Education | 薬剤を送達するための小型ポリマー担体 |
| CN110327300B (zh) * | 2019-07-23 | 2020-08-07 | 赵修文 | 一种负载药物的聚乙烯醇微球 |
| WO2022010850A1 (en) * | 2020-07-06 | 2022-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polymeric carriers for delivery of therapeutic agents |
| WO2022047544A1 (en) * | 2020-09-04 | 2022-03-10 | IP Cornerstone Pty Ltd | Minimally invasive treatment of osteoarthritis and other conditions |
| US20240207256A1 (en) * | 2021-05-12 | 2024-06-27 | Neupharma, Inc | Certain chemical entities, compositions, and methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL409579A1 (pl) * | 2001-02-19 | 2015-03-02 | Novartis Ag | Leczenie raka |
| WO2003028696A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20050220880A1 (en) * | 2002-03-07 | 2005-10-06 | Lewis Andrew L | Drug carriers comprising amphiphilic block copolymers |
| US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| CN103393605B (zh) * | 2003-02-12 | 2018-05-29 | 生物相容英国有限公司 | 用于实体瘤的化学栓塞治疗的组合物 |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| US20070275991A1 (en) * | 2004-09-07 | 2007-11-29 | Biocompatibles Uk Limited | Drug Delivery From Embolic Agents |
| US8663673B2 (en) * | 2005-07-29 | 2014-03-04 | Surmodics, Inc. | Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
-
2008
- 2008-08-18 JP JP2010520637A patent/JP2010536738A/ja active Pending
- 2008-08-18 TR TR2018/20076T patent/TR201820076T4/tr unknown
- 2008-08-18 WO PCT/GB2008/050722 patent/WO2009022190A1/en not_active Ceased
- 2008-08-18 ES ES08788693T patent/ES2706023T3/es active Active
- 2008-08-18 EP EP08788693.3A patent/EP2190409B9/en not_active Not-in-force
- 2008-08-18 US US12/672,031 patent/US20110229572A1/en not_active Abandoned
-
2014
- 2014-01-30 JP JP2014016185A patent/JP2014114307A/ja active Pending
-
2016
- 2016-06-08 JP JP2016114725A patent/JP2016216465A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016216465A5 (https=) | ||
| JP2017025071A5 (https=) | ||
| US11103450B2 (en) | Polyfunctional radical scavenger hydrogel formulation | |
| TWI610952B (zh) | 具有胺或膦官能化末端嵌段之嵌段共聚物 | |
| CN103209717B (zh) | 用于医疗设备的光滑涂层 | |
| JP6890583B2 (ja) | ポリマー基材に結合されたヒドロゲル組成物 | |
| JP6817185B2 (ja) | 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 | |
| JP2017514850A5 (https=) | ||
| BR112017016342B1 (pt) | revestimento de entrega de fármacos | |
| JP2010508902A5 (https=) | ||
| JP2016515158A5 (https=) | ||
| CN104039369A (zh) | 疏水性塞拉集宁化合物和包含该化合物的装置 | |
| ES2951187T3 (es) | Polimerosomas de fumarato | |
| JP2010524947A5 (https=) | ||
| CN114206338A (zh) | 作为pd-l1抑制剂的二氢化茚类 | |
| EP2808349A1 (en) | Triblock copolymer and use thereof | |
| TW201718768A (zh) | 藥物緩釋性醫療用隱形眼鏡 | |
| JP2011136977A5 (https=) | ||
| JP2018527360A5 (https=) | ||
| CN108290990B (zh) | 粘合性聚合物及医用粘合贴附剂 | |
| EA201501099A2 (ru) | Способ получения катионных амфифильных блок-сополимеров n, n-диметиламиноэтилметакрилата для доставки нуклеиновых кислот в живые клетки | |
| JP2019512534A5 (https=) | ||
| JP2010504318A5 (https=) | ||
| JP2009132700A5 (https=) | ||
| HRP20220151T1 (hr) | Višenamjenski sastav torasemida |